Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 69.28 · gapped above the open, then crossed back over prior close. High/low 73.31 at 5:15 am ET, 68.69 at 1:15 pm ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of CYTK revenue | Skew |
|---|---|---|---|
| KRCKilroy Realty Corp | 2.30% | 32.39% | 0.1× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In May 2024, we entered into a series of financing agreements with affiliates of Royalty Pharma, including the RP OM Loan Agreement, the RP Ulacamten RPA, the 2022 RP Multi Tranche Loan Agreement Amendment, the RP Aficamten RPA Amendment, and the RP Stock Purchase Agreement for a private placement of common stock concurrent with our underwritten public offering of common stock.”
FILING10-K0001193125-26-076495cik 0001061983
“In November 2024, we entered into a license and collaboration agreement with Bayer Consumer Care AG, an affiliate of Bayer AG, pursuant to which we granted to Bayer an exclusive license to develop and commercialize aficamten in Japan, subject to certain reserved development rights.”
FILING10-K0001193125-26-076495cik 0001061983
“10 Cytokinetics, Inc. San Francisco Bay Area 18,167 234,892 2.3% 1.4% 2033 8.8”
$29M relationship0.1× more of KRC’s book than CYTK’s
basisKRC fy2025 · closed 2025-12 $1.2BCYTK fy2025 · closed 2025-12 $88M
FILING10-K
“In December 2024, Corxel assigned its rights and obligations under our license and collaboration agreement to Genzyme Corporation, an affiliate of Sanofi.”
FILING10-K0001193125-26-076495cik 0001061983
“In February 2017, we entered into the RP OM RPA pursuant to which we sold a portion of our right to receive royalties from Amgen on future net sales of omecamtiv mecarbil to RPFT for a one-time payment of $90 million, which is non-refundable even if omecamtiv mecarbil is never commercialized.”
FILING10-K0001193125-26-076495cik 0001061983
“Pursuant to the RP Ulacamten RPA, RPI ICAV purchased the right to receive 1 % of annual net sales of ulacamten by us, our affiliates or licensees, in exchange for $ 50 million which was paid up-front.”
FILING10-K0001193125-26-076495cik 0001061983
“In December 2024, we entered into a mutual termination agreement with Corxel to terminate the Corxel OM License Agreement.”
FILING10-K0001193125-26-076495cik 0001061983
“On February 27, 2025, we entered into an Open Market Sale Agreement SM with Jefferies LLC under which we may offer and sell, from time to time, at our sole discretion, shares of Common Stock in "at the market offerings" pursuant to Rule 415(a)(4) under the Securities Act of 1933 through Jefferies LLC, as sales agent.”
FILING10-K0001193125-26-076495cik 0001061983
Watchlist prices, news filtered to it, and its next report on your desk.
Cytokinetics Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Cytokinetics Inc has 3 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Cytokinetics Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CYTK (Cytokinetics Inc) has 3 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: AMGN +0.20%, in healthcare.